ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 86 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2021. The put-call ratio across all filers is 1.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,556,040 | -15.7% | 10,969,282 | 0.0% | 0.05% | -16.9% |
| Q2 2023 | $10,146,586 | -5.3% | 10,969,282 | +11.6% | 0.06% | +1.7% |
| Q1 2023 | $10,715,656 | -25.3% | 9,830,877 | 0.0% | 0.06% | -32.6% |
| Q4 2022 | $14,353,080 | +35.8% | 9,830,877 | 0.0% | 0.09% | +24.6% |
| Q3 2022 | $10,568,000 | -36.8% | 9,830,877 | 0.0% | 0.07% | -27.4% |
| Q2 2022 | $16,712,000 | -17.5% | 9,830,877 | 0.0% | 0.10% | -18.1% |
| Q1 2022 | $20,252,000 | -45.1% | 9,830,877 | 0.0% | 0.12% | -35.2% |
| Q4 2021 | $36,866,000 | -27.5% | 9,830,877 | 0.0% | 0.18% | -19.7% |
| Q3 2021 | $50,826,000 | +21.4% | 9,830,877 | 0.0% | 0.22% | +21.2% |
| Q2 2021 | $41,880,000 | -19.8% | 9,830,877 | 0.0% | 0.18% | -18.6% |
| Q1 2021 | $52,202,000 | -1.5% | 9,830,877 | 0.0% | 0.23% | +13.0% |
| Q4 2020 | $52,988,000 | +4.9% | 9,830,877 | +55.3% | 0.20% | -1.0% |
| Q3 2020 | $50,516,000 | -24.4% | 6,330,354 | -5.2% | 0.20% | -31.5% |
| Q2 2020 | $66,819,000 | +565.7% | 6,675,181 | +80.9% | 0.30% | +375.8% |
| Q1 2020 | $10,038,000 | +745.7% | 3,690,307 | +3590.3% | 0.06% | +588.9% |
| Q2 2018 | $1,187,000 | +5.7% | 100,000 | 0.0% | 0.01% | -10.0% |
| Q1 2018 | $1,123,000 | +68.1% | 100,000 | 0.0% | 0.01% | +66.7% |
| Q4 2017 | $668,000 | -18.4% | 100,000 | 0.0% | 0.01% | -14.3% |
| Q3 2017 | $819,000 | +82.4% | 100,000 | 0.0% | 0.01% | +75.0% |
| Q2 2017 | $449,000 | -18.5% | 100,000 | 0.0% | 0.00% | -20.0% |
| Q1 2017 | $551,000 | +36.0% | 100,000 | 0.0% | 0.01% | +25.0% |
| Q4 2016 | $405,000 | -42.6% | 100,000 | 0.0% | 0.00% | -33.3% |
| Q3 2016 | $705,000 | -13.5% | 100,000 | 0.0% | 0.01% | -33.3% |
| Q2 2016 | $815,000 | +0.2% | 100,000 | 0.0% | 0.01% | 0.0% |
| Q1 2016 | $813,000 | -32.6% | 100,000 | 0.0% | 0.01% | -10.0% |
| Q4 2015 | $1,206,000 | +0.8% | 100,000 | 0.0% | 0.01% | -9.1% |
| Q3 2015 | $1,197,000 | -34.7% | 100,000 | 0.0% | 0.01% | -31.2% |
| Q2 2015 | $1,833,000 | – | 100,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 6,287,101 | $4,903,939 | 2.63% |
| Syncona Portfolio Ltd | 1,377,294 | $1,074,289 | 1.60% |
| MPM BioImpact LLC | 5,095,912 | $3,974,811 | 1.06% |
| NEA Management Company, LLC | 17,079,778 | $13,322,227 | 1.03% |
| TANG CAPITAL MANAGEMENT LLC | 5,166,954 | $4,030,224 | 0.57% |
| PFM Health Sciences, LP | 10,423,135 | $8,130,045 | 0.38% |
| Matrix Capital Management Company, LP | 38,974,185 | $30,399,864 | 0.36% |
| Long Focus Capital Management, LLC | 10,963,158 | $8,551,263 | 0.31% |
| Acuitas Investments, LLC | 479,764 | $374,216 | 0.22% |
| Endurant Capital Management LP | 311,944 | $243,316 | 0.22% |